Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1CNS 1

Conditions

Breast Neoplasms 2Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × gadobutrol × Clear all
NCT00522951 2017-08-28

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Bayer

Phase 3 Completed
165 enrolled 24 charts
CNS

Brain Neoplasms

NCT01050829 2014-12-30

Gadobutrol Magnevist-controlled Body Study

Bayer

Phase 3 Completed
370 enrolled
Tumor-Agnostic

Neoplasms

NCT01067976 2014-11-11

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Bayer

Phase 3 Completed
446 enrolled 30 charts
Breast

Breast Neoplasms

NCT01104584 2014-11-11

GEMMA 2

Bayer

Phase 3 Completed
460 enrolled 31 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡